Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Roostaee, Alireza ^a   Beaudoin, Simon ^a   Staskevicius, Antanas ^a   Roucou, Xavier ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; DIMER; LIGAND; OLIGOMER; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CHIMERA; CONFORMATION; CONTROLLED STUDY; DIMERIZATION; EXPERIMENT; HIPPOCAMPUS; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; HIPPOCAMPUS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS;

MUS;

EID: 84872458771     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-5     Document Type: Article

References (59)

1. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T, Am J Pathol 1998 152 4 879 884 9546347
2. Alpha-synuclein and neurodegenerative diseases. Goedert M, Nat Rev Neurosci 2001 2 7 492 501 10.1038/35081564 11433374
3. Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. Mori F, Piao YS, Hayashi S, Fujiwara H, Hasegawa M, Yoshimoto M, Iwatsubo T, Takahashi H, Wakabayashi K, J Neuropathol Exp Neurol 2003 62 8 812 819 14503637
4. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A, Neuron 2000 25 1 239 252 10.1016/S0896- 6273(00)80886-7 10707987
5. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Maroteaux L, Scheller RH, Brain Res Mol Brain Res 1991 11 3-4 335 343 1661825
6. Identification of two distinct synucleins from human brain. Jakes R, Spillantini MG, Goedert M, FEBS Lett 1994 345 1 27 32 10.1016/0014-5793(94) 00395-5 8194594
7. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M, J Biol Chem 1998 273 41 26292 26294 10.1074/jbc.273.41.26292 9756856
8. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG, Ann Neurol 2004 55 2 164 173 10.1002/ana.10795 14755719
9. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K, Nat Rev Neurosci 2003 4 9 727 738 10.1038/nrn1199 12951565
10. Conformational diseases: looking into the eyes. Surguchev A, Surguchov A, Brain Res Bull 2010 81 1 12 24 10.1016/j.brainresbull.2009.09.015 19808079
11. Prion-like transmission of protein aggregates in neurodegenerative diseases. Brundin P, Melki R, Kopito R, Nat Rev Mol Cell Biol 2010 11 4 301 307 10.1038/nrm2873 20308987
12. The most infectious prion protein particles. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B, Nature 2005 437 7056 257 261 10.1038/nature03989 16148934
13. Cell systems and the toxic mechanism(s) of alpha-synuclein. Cookson MR, van der Brug M, Exp Neurol 2008 209 1 5 11 10.1016/j.expneurol.2007.05.022 17603039
14. Aggregation and amyloid fibril formation induced by chemical dimerization of recombinant prion protein in physiological-like conditions. Roostaee A, Cote S, Roucou X, J Biol Chem 2009 284 45 30907 30916 10.1074/jbc.M109.057950 19710507
15. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG, Science 2003 300 5618 486 489 10.1126/science.1079469 12702875
16. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, Wender N, Kim HY, Taschenberger G, Falkenburger BH, Heise H, Kumar A, Riedel D, Fichtner L, Voigt A, Braus GH, Giller K, Becker S, Herzig A, Baldus M, Jackle H, Eimer S, Schulz JB, Griesinger C, Zweckstetter M, EMBO J 2009 28 20 3256 3268 10.1038/emboj.2009.257 19745811
17. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr, Proc Natl Acad Sci U S A 2000 97 2 571 576 10.1073/pnas.97.2.571 10639120
18. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Conway KA, Harper JD, Lansbury PT Jr, Biochemistry 2000 39 10 2552 2563 10.1021/bi991447r 10704204
19. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Haass C, Selkoe DJ, Nat Rev Mol Cell Biol 2007 8 2 101 112 10.1038/nrm2101 17245412
20. In vitro and in vivo neurotoxicity of prion protein oligomers. Simoneau S, Rezaei H, Sales N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C, Fournier JG, Comte J, Wopfner F, Grosclaude J, Schatzl H, Lasmezas CI, PLoS Pathog 2007 3 8 125 10.1371/journal.ppat.0030125 17784787
21. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ, Proc Natl Acad Sci U S A 2009 106 31 13010 13015 10.1073/pnas.0903691106 19651612
22. Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. Yonetani M, Nonaka T, Masuda M, Inukai Y, Oikawa T, Hisanaga S, Hasegawa M, J Biol Chem 2009 284 12 7940 7950 10.1074/jbc.M807482200 19164293
23. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM, Proc Natl Acad Sci U S A 2009 106 47 20051 20056 19892735
24. The propagation of prion-like protein inclusions in neurodegenerative diseases. Goedert M, Clavaguera F, Tolnay M, Trends Neurosci 2010 33 7 317 325 10.1016/j.tins.2010.04.003 20493564
25. Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. Congdon EE, Kim S, Bonchak J, Songrug T, Matzavinos A, Kuret J, J Biol Chem 2008 283 20 13806 13816 10.1074/jbc.M800247200 18359772
26. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Yamasaki M, Li W, Johnson DJ, Huntington JA, Nature 2008 455 7217 1255 1258 10.1038/nature07394 18923394
27. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Iwata A, Maruyama M, Akagi T, Hashikawa T, Kanazawa I, Tsuji S, Nukina N, Hum Mol Genet 2003 12 20 2625 2635 10.1093/hmg/ddg283 12928483
28. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W, Wypych J, Randolph TW, Narhi LO, Biere AL, Citron M, Carpenter JF, Biochemistry 2003 42 3 829 837 10.1021/bi026528t 12534296
29. Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. Zhou W, Freed CR, J Biol Chem 2004 279 11 10128 10135 14699135
30. Lindquist S: alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Auluck PK, Caraveo G, Annu Rev Cell Dev Biol 2010 26 211 233 10.1146/annurev.cellbio.042308.113313 20500090
31. Controlling signal transduction with synthetic ligands. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR, Science 1993 262 5136 1019 1024 10.1126/science.7694365 7694365
32. Proximity-induced activation of human Cdc34 through heterologous dimerization. Gazdoiu S, Yamoah K, Wu K, Escalante CR, Tappin I, Bermudez V, Aggarwal AK, Hurwitz J, Pan ZQ, Proc Natl Acad Sci U S A 2005 102 42 15053 15058 10.1073/pnas.0507646102 16210246
33. Aggregation of cellular prion protein is initiated by proximity-induced dimerization. Goggin K, Bissonnette C, Grenier C, Volkov L, Roucou X, J Neurochem 2007 102 4 1195 1205 10.1111/j.1471-4159.2007.04611.x 17663754
34. Induced dimerization of the amyloid precursor protein leads to decreased amyloid-beta protein production. Eggert S, Midthune B, Cottrell B, Koo EH, J Biol Chem 2009 284 42 28943 28952 10.1074/jbc.M109.038646 19596858
35. In vitro generation of infectious scrapie prions. Castilla J, Saa P, Hetz C, Soto C, Cell 2005 121 2 195 206 10.1016/j.cell.2005.02.011 15851027
36. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA, Proc Natl Acad Sci U S A 2000 97 9 4897 4902 10.1073/pnas.97.9.4897 10781096
37. Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation. Anderson VL, Ramlall TF, Rospigliosi CC, Webb WW, Eliezer D, Proc Natl Acad Sci U S A 2010 107 44 18850 18855 10.1073/pnas. 1012336107 20947801
38. Quantification of beta-sheet amyloid fibril structures with thioflavin T. LeVine H 3rd, Methods Enzymol 1999 309 274 284 10507030
39. ANS binding reveals common features of cytotoxic amyloid species. Bolognesi B, Kumita JR, Barros TP, Esbjorner EK, Luheshi LM, Crowther DC, Wilson MR, Dobson CM, Favrin G, Yerbury JJ, ACS Chem Biol 2010 5 8 735 740 10.1021/cb1001203 20550130
40. A causative link between the structure of aberrant protein oligomers and their toxicity. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, Relini A, Stefani M, Dobson CM, Cecchi C, Chiti F, Nat Chem Biol 2010 6 2 140 147 10.1038/nchembio.283 20081829
41. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E, Gilden D, Oldstone MB, Conti B, Williamson RA, Science 2004 303 5663 1514 1516 10.1126/science.1094273 14752167
42. Parkinson's disease: mechanisms and models. Dauer W, Przedborski S, Neuron 2003 39 6 889 909 10.1016/S0896-6273(03)00568-3 12971891
43. Staging of brain pathology related to sporadic Parkinson's disease. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E, Neurobiol Aging 2003 24 2 197 211 10.1016/S0197-4580(02)00065-9 12498954
44. Is Parkinson's disease a prion disorder? Olanow CW, Prusiner SB, Proc Natl Acad Sci U S A 2009 106 31 12571 12572 10.1073/pnas.0906759106 19666621
45. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM, Science 2012 338 6109 949 953 10.1126/science.1227157 23161999
46. Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment. Kim HJ, Chatani E, Goto Y, Paik SR, J Microbiol Biotechnol 2007 17 12 2027 2032 18167451
47. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ, Nat Med 2008 14 8 837 842 10.1038/nm1782 18568035
48. In vitro formation of amyloid from alpha-synuclein is dominated by reactions at hydrophobic interfaces. Pronchik J, He X, Giurleo JT, Talaga DS, J Am Chem Soc 2010 132 28 9797 9803 10.1021/ja102896h 20578692
49. Formation of toxic oligomeric alpha-synuclein species in living cells. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ, PLoS One 2008 3 4 1867 10.1371/journal.pone.0001867 18382657
50. Liu CW: alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. Zhang NY, Tang Z, J Biol Chem 2008 283 29 20288 20298 10.1074/jbc.M710560200 18502751
51. In vivo demonstration that alpha-synuclein oligomers are toxic. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R, Proc Natl Acad Sci U S A 2011 108 10 4194 4199 10.1073/pnas.1100976108 21325059
52. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. Stefani M, Dobson CM, J Mol Med (Berl) 2003 81 11 678 699 10.1007/s00109-003-0464-5
53. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Li JY, Englund E, Widner H, Rehncrona S, Bjorklund A, Lindvall O, Brundin P, Mov Disord 2010 25 8 1091 1096 10.1002/mds.23012 20198645
54. Prion-like mechanisms in neurodegenerative diseases. Frost B, Diamond MI, Nat Rev Neurosci 2010 11 3 155 159 20029438
55. Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. Giannakis E, Pacifico J, Smith DP, Hung LW, Masters CL, Cappai R, Wade JD, Barnham KJ, Biochim Biophys Acta 2008 1778 4 1112 1119 10.1016/j.bbamem.2008.01.012 18261456
56. Are synucleinopathies prion-like disorders? Angot E, Steiner JA, Hansen C, Li JY, Brundin P, Lancet Neurol 2010 9 11 1128 1138 10.1016/S1474-4422(10) 70213-1 20846907
57. Cysteine misincorporation in bacterially expressed human alpha-synuclein. Masuda M, Dohmae N, Nonaka T, Oikawa T, Hisanaga S, Goedert M, Hasegawa M, FEBS Lett 2006 580 7 1775 1779 10.1016/j.febslet.2006.02.032 16513114
58. Cholesterol binding is a prerequisite for the activity of the steroidogenic acute regulatory protein (StAR). Roostaee A, Barbar E, Lehoux JG, Lavigne P, Biochem J 2008 412 3 553 562 10.1042/BJ20071264 18341481
59. Physiological buffers for NMR spectroscopy. Freund J, Kalbitzer HR, J Biomol NMR 1995 5 321 322 22911504